These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 8695369

  • 1. A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor.
    Smith I, Jones A, Spielmann M, Namer M, Green MD, Bonneterre J, Wander HE, Hatschek T, Wilking N, Zalcberg J, Spiers J, Seymour L.
    Br J Cancer; 1996 Aug; 74(3):479-81. PubMed ID: 8695369
    [Abstract] [Full Text] [Related]

  • 2. 'Tomudex' (ZD1694): a novel thymidylate synthase inhibitor with clinical antitumour activity in a range of solid tumours. 'Tomudex' International Study Group.
    Cunningham D, Zalcberg J, Smith I, Gore M, Pazdur R, Burris H, Meropol NJ, Kennealey G, Seymour L.
    Ann Oncol; 1996 Feb; 7(2):179-82. PubMed ID: 8777175
    [Abstract] [Full Text] [Related]

  • 3. ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group.
    Zalcberg JR, Cunningham D, Van Cutsem E, Francois E, Schornagel J, Adenis A, Green M, Iveson A, Azab M, Seymour I.
    J Clin Oncol; 1996 Mar; 14(3):716-21. PubMed ID: 8622016
    [Abstract] [Full Text] [Related]

  • 4. 'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The 'Tomudex' Colorectal Cancer Study Group.
    Cunningham D, Zalcberg JR, Rath U, Olver I, Van Cutsem E, Svensson C, Seitz JF, Harper P, Kerr D, Perez-Manga G.
    Eur J Cancer; 1995 Nov; 31A(12):1945-54. PubMed ID: 8562146
    [Abstract] [Full Text] [Related]

  • 5. Phase II study of ZD1694 in patients with advanced gastric cancer.
    Meropol NJ, Pazdur R, Vincent M, Willson JK, Kelsen DP, Douglass HO.
    Am J Clin Oncol; 1996 Dec; 19(6):628-30. PubMed ID: 8931686
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Phase II trial of ZD1694 (Tomudex) in patients with advanced pancreatic cancer.
    Pazdur R, Meropol NJ, Casper ES, Fuchs C, Douglass HO, Vincent M, Abbruzzese JL.
    Invest New Drugs; 1996 Dec; 13(4):355-8. PubMed ID: 8824356
    [Abstract] [Full Text] [Related]

  • 8. Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors.
    Clarke SJ, Hanwell J, de Boer M, Planting A, Verweij J, Walker M, Smith R, Jackman AL, Hughes LR, Harrap KR, Kennealey GT, Judson IR.
    J Clin Oncol; 1996 May; 14(5):1495-503. PubMed ID: 8622063
    [Abstract] [Full Text] [Related]

  • 9. Tomudex (ZD1694, NSC 639186) in platinum-pretreated recurrent epithelial ovarian cancer: a phase II study by the Gynecologic Oncology Group.
    Muggia FM, Blessing JA, Homesley HD, Sorosky J.
    Cancer Chemother Pharmacol; 1998 May; 42(1):68-70. PubMed ID: 9619760
    [Abstract] [Full Text] [Related]

  • 10. Tomudex (ZD1694): from concept to care, a programme in rational drug discovery.
    Jackman AL, Boyle FT, Harrap KR.
    Invest New Drugs; 1996 May; 14(3):305-16. PubMed ID: 8958186
    [Abstract] [Full Text] [Related]

  • 11. [A late phase II study of raltitrexed (ZD 1694) in chemotherapy-naive patients with advanced colorectal cancer].
    Nishisho I, Kikkawa N, Ebata T, Osanai H, Ujiie S, Mitachi Y, Tsutsui M, Sawai K, Nishiguchi Y, Yasutake K, Wakasugi H, Wakui A.
    Gan To Kagaku Ryoho; 2000 Jan; 27(1):81-91. PubMed ID: 10660737
    [Abstract] [Full Text] [Related]

  • 12. Phase II trial of raltitrexed ('Tomudex') in advanced small-cell lung cancer.
    Woll PJ, Basser R, Le Chevalier T, Drings P, Perez Manga G, Adenis A, Seymour L, Smith F, Thatcher N.
    Br J Cancer; 1997 Jan; 76(2):264-5. PubMed ID: 9231930
    [Abstract] [Full Text] [Related]

  • 13. ZD1694 (Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer.
    Jackman AL, Farrugia DC, Gibson W, Kimbell R, Harrap KR, Stephens TC, Azab M, Boyle FT.
    Eur J Cancer; 1995 Jan; 31A(7-8):1277-82. PubMed ID: 7577036
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. 'Tomudex' (raltitrexed) development: preclinical, phase I and II studies.
    Judson IR.
    Anticancer Drugs; 1997 Aug; 8 Suppl 2():S5-9. PubMed ID: 9376637
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Raltitrexed (tomudex) administration in patients failing multiple prior chemotherapy regimens in advanced colorectal cancer: a pilot study.
    Tsavaris N, Kosmas C, Vadiaka M, Kontos A, Fotia M, Angelopoulou A, Vrizidis N, Soulla M, Sougioultzis S, Koufos Ch.
    Invest New Drugs; 2002 Feb; 20(1):133-6. PubMed ID: 12003191
    [Abstract] [Full Text] [Related]

  • 19. Raltitrexed. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer.
    Gunasekara NS, Faulds D.
    Drugs; 1998 Mar; 55(3):423-35. PubMed ID: 9530547
    [Abstract] [Full Text] [Related]

  • 20. Overview of the tolerability of 'Tomudex' (raltitrexed): collective clinical experience in advanced colorectal cancer.
    Zalcberg J.
    Anticancer Drugs; 1997 Aug; 8 Suppl 2():S17-22. PubMed ID: 9376633
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.